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Abstract
Background—Metabolic syndrome (MetS) is an important etiologic and prognostic factor for
cancer, but few studies have assessed hospitalization outcomes among patients with both
conditions.
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Methods—Data was obtained from the Healthcare Cost and Utilization project Nationwide
Inpatient Sample (HCUP-NIS). Study variables were assessed using ICD-9 codes on adults aged
40 years and over admitted to a US hospital between 2007 and 2011 with primary diagnosis of
either breast, colorectal, or prostate cancer. We examined in-hospital mortality, post-surgical
complications, and discharge disposition among cancer patients with MetS and compared with
non-MetS patients.
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Results—Hospitalized breast (OR: 0.31, 95% CI: 0.20–0.46), colorectal (OR: 0.41, 95% CI:
0.35–0.49), and prostate (OR: 0.28, 95% CI: 0.16–0.49) cancer patients with MetS had
significantly reduced odds of in-hospital mortality. The odds of post-surgical complications among
breast (OR: 1.20, 95% CI: 1.03–1.39) and prostate (OR: 1.22, 95% CI: 1.09–1.37) cancer patients
with MetS were higher, but lower by 7% among colorectal cancer patients with MetS.
Additionally, breast (OR: 1.21, 95% CI: 1.11–1.32) and colorectal (OR: 1.06, 95% CI: 1.01–1.11)
cancer patients with MetS had significantly higher odds for discharge to a skilled nursing facility
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compared with those without MetS, but this was not statistically significant among prostate cancer
patients.
Conclusions—Adverse health outcomes were significantly higher among hospitalized patients
with a primary diagnosis of cancer and MetS. Future studies are needed to identify clinical
strategies for detecting and managing patients with MetS to reduce the likelihood of poor inpatient
outcomes.
Keywords
Metabolic syndrome; Cancer; In-hospital mortality; Inpatient outcomes

Introduction
Author Manuscript

Incidence rates for cancer and metabolic syndrome (MetS) have continued to increase
dramatically in the USA and globally [34]. MetS is defined clinically as a cluster of
interrelated biochemical conditions that include abdominal obesity, insulin resistance,
dyslipidemia, and hypertension, and this condition has been associated with significantly
increased risk for coronary heart disease, stroke, and type 2 diabetes [8, 24, 27, 33]. Recent
epidemiologic evidence also suggests that MetS is an important etiologic factor for the
development of cancer [47], as well as poor prognosis for common cancer types including
breast and colorectal cancer [20]. The prevalence of both MetS and cancer increases
dramatically with age [46], and with the rapid aging of the US population, adverse health
outcomes for millions of adults, as well as healthcare costs, are likely to be significant [11].
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Currently, at least a third of the general US adult population meet the current clinical criteria
for MetS based on analysis of the National Health and Nutritional Survey (NHANES 2003–
2012), with prevalence increasing to about 50% among those ages 60 years and older [1].
Individual components such as obesity [15], diabetes [6, 37], and hypertension [19, 23] have
long been shown to increase the risk of medical complications, overall and cancer-specific
mortality. However, health outcomes among hospitalized patients, who are likely older, more
vulnerable, and with more severe health-related conditions, have not been well evaluated.
Prior studies have reported strong positive associations between MetS and incidence and
mortality due to breast [12, 20], colorectal [5, 20], liver [20], and bladder cancers [20], but
hospitalized patients, particularly those with the most common cancer types in US adults
(breast, prostate, and colorectal cancer), need further study. Hence, the purpose of this study
is to examine health outcomes, specifically in-hospital mortality, post-surgical
complications, and discharge disposition, among hospitalized cancer patients with a clinical
diagnosis of MetS.
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Methods
Study Population
This cross-sectional study was conducted among breast, colorectal, and prostate cancer
patients ages 40 years and older admitted to a US hospital between 2007 and 2011. Clinical
data were obtained from the Healthcare Cost and Utilization Project (HCUP) Nationwide
Inpatient Sample (NIS), which covers over 1000 hospitals in the USA and includes data on
Obes Surg. Author manuscript; available in PMC 2019 March 01.
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over seven million hospital stays. Further details about NIS can be obtained from http://
www.hcupus.ahrq.gov/nisoverview.jsp.
Clinical and Individual Variables
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International Classification of Disease, ninth edition ICD-9 codes for breast (ICD-9 codes:
174.x), colorectal (ICD-9 codes: 153.x, 154.0–154.3, 154.8), and prostate cancer (ICD-9
code: 185) recorded during admissions were assessed. Patients in whom the diagnosis of
interest was not coded in first two diagnostic fields were excluded in order to exclude
patients with underlying conditions. In addition, data on race, age, gender, area-level
income, residential region, and insurance status were obtained from the NIS dataset. As
cancer stage data is not captured in the dataset, a proxy cancer stage variable was created
using the clinical criteria of disease staging, with patients categorized as metastatic when
ICD-9 code indicated metastatic disease to other organs (196.x, 197.x, 198.x, 199.0–199.1)
and non-metastatic when those codes were absent. Several studies have used similar staging
criteria using the HCUP-NIS database [4]. Hospital length of stay was calculated by
subtracting the number of days between admission and discharge, with same-day stays
coded as 0. Surgical treatment for breast, colorectal, and prostate cancer was classified using
diagnostic and procedure codes similar to those used in prior studies with HCUP NIS data
(ICD-9 codes: breast: 85.41–85.48, 85.20–85.23; colorectal: 17.33–17.36, 17.39, 45.7×,
45.80–45.82, 48.42–48.43, 48.49, 48.50–48.52, 48.63–48.65; prostate: 60.2–60.6) [2, 3, 32].
Study Exposure
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Metabolic syndrome (MetS) was defined based on diagnosis codes (ICD-9 code: 277.7) or
having at least three out of five components of MetS, namely, high blood pressure (ICD-9
codes: 401–405), BMI ≥ 30 (ICD-9 codes: V85.3-V85.4, 278.01, 278.03), altered fasting
glucose (ICD-9 codes: 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 250.32,
250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90,
250.92), low HDL cholesterol (ICD-9 codes: 272.5–272.6), and high triglycerides (ICD-9
codes: 272.1–272.4). This definition was chosen to approximate the definition published by
the US National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)
[7] previously examined in the NIS database [31] and Surveillance, Epidemiology, and End
Results-Medicare database [42]. A modified Deyo comorbidity index [4] was created to
account for the number of comorbid conditions present upon admission among patients, and
those included myocardial infarction, chronic heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic
ulcer disease, mild liver disease, hemiplegia, paraplegia, renal disease, liver disease, and
HIV/AIDS.
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Outcome Measures
The main study outcomes assessed for cancer patients were in-hospital mortality, postsurgical complications, and discharge disposition. In-hospital mortality was defined as
deaths occurring during hospitalization; post-surgical complication was defined using ICD-9
codes associated with mechanical wounds, infection, renal, gastrointestinal, cardiovascular
or pulmonary complications, as well as intra-operative complications. Discharge disposition
is based on whether patients are discharged to recover at home or in other facilities such as
Obes Surg. Author manuscript; available in PMC 2019 March 01.
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Statistical Analysis
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nursing homes, and was classified into the following: (1) routine discharge: discharged to
home or self-care; (2) discharge to a skilled nursing facility; (3) expired/died; and (4) other
—classified as discharged due to any other reasons not stated above [10, 16].

Results

Descriptive statistics was conducted using Chi-square tests for categorical variables and t
test for continuous variables, and the proportion of cancer in patients with MetS was
assessed. Multivariable logistic regression analysis was used to determine the association
between MetS and in-hospital mortality, complications, and discharge disposition separately
for breast cancer in women only, prostate cancer in men only, and colorectal cancer in both
men and women. All models were adjusted for age, race, stage, income, insurance and
residential region, number of comorbidities, treatment, stage, and length of stay.
Additionally, models for discharge disposition and in-hospital mortality were also adjusted
for complications, and models for colorectal cancer were also adjusted for gender. All
statistical analyses were performed with SAS 9.4 (Cary, NC).
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MetS was present in 5.2, 6.9, and 5.5% of hospitalized breast (70,916), colorectal (152,952),
and prostate (87,623) cancer patients, respectively (Table 1). MetS was more prevalent in the
older age groups of 60–69 years (7.3% in breast, 8.6% in colorectal, and 6.2% in prostate
patients) compared with younger age groups (1.4% in breast, 2.6% in colorectal, and 2.9%
in prostate cancer). For breast (8.% vs. 4.5%), colorectal (7.4% vs. 6.7%), and prostate
(7.6% vs. 4.9%) cancer patients, MetS prevalence was higher among Blacks compared to
Whites. In addition, patients residing in the lowest socioeconomic status (SES) regions had
higher prevalence of MetS compared with those in the highest SES regions across all three
cancer types. Regardless of cancer type, patients on Medicare had much higher MetS
prevalence compared with those with private or other insurance types.
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After adjusting for demographics, SES, insurance, and stage (Table 2), breast (OR: 0.31,
95% CI: 0.20–0.46) and prostate (OR: 0.28, 95% CI: 0.16–0.49) cancer patients with MetS
had a 70–80% lower odds of in-hospital deaths, while colorectal cancer patients experienced
about 60% reduced odds (OR: 0.41, 95% CI: 0.35–0.49). However, increasing number of
comorbidities was associated with about 43% increased odds of in-hospital mortality across
the three cancer types (breast: OR: 1.43, 95% CI: 1.31–1.57; colorectal: OR: 1.46, 95% CI:
1.41–1.51; prostate: OR: 1.44, 95% CI: 1.31–1.58), excluding comorbid conditions included
in the definition of MetS. There was a 20–22% increased odds of post-surgical
complications among breast (OR: 1.20, 95% CI: 1.03–1.39) and prostate (OR: 1.22, 95% CI:
1.09–1.37) cancer patients with MetS, but a 7% decreased odds among colorectal cancer
patients (OR: 0.93, 95% CI: 0.88–0.99) with MetS (Table 3). Increasing number of
comorbid conditions also increased the odds of post-surgical complications among breast
cancer patients (OR: 1.10, 95% CI: 1.03–1.17), but reduced the odds among colorectal
cancer patients (OR: 0.90, 95% CI: 0.88–0.92). Breast (OR: 1.21, 95% CI: 1.11–1.32) and
colorectal (OR: 1.06, 95% CI: 1.01–1.11) cancer patients with MetS were significantly more
likely to be discharged to a skilled nursing facility compared with those without MetS (Table

Obes Surg. Author manuscript; available in PMC 2019 March 01.
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4). Prostate cancer patients with MeS were also 10% more likely to be discharged to skilled
nursing facilities; however, this was not statistically significant.

Discussion
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In a large dataset of hospitalized cancer patients, we observed that 5 to 7% of breast,
colorectal, and prostate cancer patients met the criteria for MetS using the NCEP ATP III
definition [7]. The observed prevalence of MetS among hospitalized cancer patients
increased with age and was much higher among Blacks and Hispanics compared with
Whites, and higher among residents of lower SES regions compared with higher SES
regions. These demographic patterns are similar to those observed in the general US
population [1], and other studies have reported a prevalence of about 9% among patient
populations in the HCUP NIS [31]. About a third of the general US adult population
currently meets the criteria for MetS, with significantly increasing trends observed in the
past few decades [41]. Differences in the availability of relevant data items in routine
healthcare claim databases such as the HCUP likely contributed to our observed lower
estimate. Nevertheless, significant increases in the prevalence of MetS are expected to
continue due to demographic changes (due to the aging of the US population) and trends in
lifestyle risk factors (such as obesity, physical activity, and diet). These risk factors also
independently contribute to cancer risk and prognosis, making the assessment of the impact
of metabolic syndrome on cancer outcomes highly relevant.

Author Manuscript
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We observed that breast, colorectal, and prostate cancer patients with MetS had lower odds
of in-hospital mortality, but higher odds of post-surgical complications and discharge to
skilled nursing facilities. Other studies have reported a positive association between MetS
and cancer mortality [17, 25, 43] with result showing increased risk of cancer-related
mortality among individuals with MetS, and other studies have reported increased risk of
post-surgical complications among patients with MetS [30]. Our finding of an inverse
association between MetS and in-hospital mortality may be due to several factors: (1)
differences in the specific MetS criteria used, (2) tumor-specific differences in the
association between MetS and cancer mortality that may be masked by examining overall
cancer mortality, and/or (3) differences in study population examined. In this study, we
focused on hospitalized cancer patients, who are likely to be at more advanced stages of
disease and hospitalized for surgery or treatment of other cancer-related complications. This
study population is also unique in several ways. For instance, the severity of the cancer
diagnosis and complicated treatment process may have led to mis-classification of MetS
status if relevant data on diabetes, cholesterol, or BMI are not routinely captured/recorded in
the medical records. In addition, an underlying MetS condition may be considered
secondary to the primary cancer diagnosis during admission, and thus not addressed or
evaluated during hospitalization. In addition, since MetS is associated with poorer
hospitalization outcomes [9, 36, 38], this may have resulted in our observed higher odds of
post-surgical complications and non-routine discharge, in which case mortality outcomes
will occur outside of the hospital setting and thus will not be captured in the dataset.
There were increased odds of post-operative complications among breast and prostate cancer
patients with MetS, but decreased odds for patients with colorectal cancer. This may be due

Obes Surg. Author manuscript; available in PMC 2019 March 01.
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to differences in the types of surgical procedures. A major innovation in recent surgical
techniques was the development of laparoscopic surgery for colon and prostate cancer [21,
29, 45]. This less-invasive surgery type has been associated with significantly reduced rates
of post-surgical complications, and a recent study observed that MetS was associated with
poorer post-surgical outcomes following radical prostatectomy compared with those who
received laparoscopic surgery [39]. We also observed significantly higher odds of breast and
colorectal cancer patients with MetS to be discharged to skilled facilities. Our findings
corroborate the existing literature showing that cancer patients with perioperative events,
comorbidities, and surgical complications were at higher risk for rapid postoperative
functional decline, leading to discharge to skilled facilities [16, 18, 44]. Taken together,
these results suggest that the inverse association observed between MetS and in-hospital
mortality is likely an artifact of the greater likelihood for these patients to experience postsurgical complications and to be discharged to nursing facilities.
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Given that millions of US adults currently meet the criteria for MetS, especially at older ages
when the risk of chronic diseases like cancer is also highest, it is inevitable that a significant
proportion of hospitalized patients will experience complications or adverse health outcomes
more severe than indicated due to their current health condition. The question of whether
health outcomes among cancer patients can be improved by controlling or eliminating MetS
awaits large prospective studies. However, there is growing recognition of the importance of
MetS as a significant public health issue, due to its independent association with worse
health outcomes, as well as its role as an etiologic and/or prognostic risk factor for many
other chronic diseases including cardiovascular diseases, stroke, chronic kidney diseases,
and Alzheimer’s disease. MetS is also associated with increased healthcare utilization,
longer hospital stay, increased healthcare costs, and need for post-hospitalization care. A
critical need will be to identify which approaches should be taken to address or resolve
components of MetS among pre-, peri-, or postoperative patients, who are at increased risk
of complications. Hospitalized cancer patients with MetS may benefit from holistic clinical
approaches to recognize components of MetS and its potential impact on health outcomes,
and management strategies combining nutritional changes (e.g., low-carbohydrate dietary
patterns shown to improve HDL, glucose, and HbA1C levels [13, 14, 22], prescribed
physical activity (e.g., 30-min moderate physical activity 3–4 days/week to improve blood
pressure and glycemic control [28, 40]), and/or the use of statins as lipid-lowering agents
[35]. Future studies will be required to formally evaluate whether these combined
behavioral/lifestyle approaches among cancer patients may improve post-operative outcomes
and improve survival.
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Several strengths and limitations are relevant to these study results. First, there is very little
direct evidence regarding inpatient outcomes among adults with clinical diagnoses of MetS
and cancer, despite the high prevalence of MetS in US adults, the common risk factors
shared by both conditions, and the vulnerability of hospitalized patients. Second, use of the
Nationwide Inpatient Survey provided objective clinical claims data on MetS and cancer
diagnosis on a large sample of US adults, with baseline socio-demographic data that allowed
us to adjust for potential confounders. As with most studies based on administrative claim
database, the study was also subject to several limitations. First, our operational definition of
MetS relied exclusively on ICD-9 codes documented in the NIS database and may be
Obes Surg. Author manuscript; available in PMC 2019 March 01.
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vulnerable to misclassification and under-classification especially for MetS. The definition
of MetS is ever-evolving [26] and included measurements of cholesterolemia,
triglyceridemia, fasting plasma glycemia, and waist circumference. These may not always be
assessed during admission for a primary diagnosis of cancer or may not be consistently
recorded as diagnosis codes, potentially explaining the lower prevalence of MetS in our
study sample. MetS was defined here based on the presence of diagnosis codes for at least
three out of five components, following the definition proposed by the US National
Cholesterol Education Program Adult Treatment Panel III [7] and similar to the
methodology reported by other investigators [1, 31, 42]. Second, due to the cross-sectional
nature of the dataset, we are unable to directly assess causality or account for individuals
who have MetS components that are well controlled with medication. Nevertheless, we
observed significantly worse health outcomes among patients with clinical diagnoses of
MetS and cancer that warrant the early identification of these patients and formulation of
clinical strategies to manage or eliminate components of MetS prior to surgery. Future
studies are also needed to provide critical information regarding prevention and treatment
strategies most appropriate for cancer patients, especially those who are sicker and
hospitalized.
In conclusion, hospitalized patients with MetS and clinical diagnosis of breast, colorectal,
and prostate cancer were less likely to experience in-hospital mortality, but were more likely
to experience post-surgical complications and non-routine discharge to skilled nursing
facilities. Clinical strategies for timely identification and control of MetS components may
go a long way in reducing these adverse health outcomes among hospitalized patients.
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Table 1

Author Manuscript

Prevalence of metabolic syndrome (MetS) among patients with cancer; Nationwide Inpatient Sample 2007–
2011
Metabolic syndrome present N (%)

Author Manuscript

Breast cancer

Colorectal cancer

Prostate cancer

N

70,916

152,952

87,623

Overall with MetS

3702 (5.22)

10,543 (6.89)

4777 (5.45)

40–49

210 (1.43)

360 (2.62)

108 (2.87)

50–59

730 (1.03)

1612 (5.33)

1048 (4.39)

60–69

1278 (7.34)

3215 (8.57)

2339 (6.25)

70 and above

1484 (7.26)

5356 (7.50)

1282 (5.68)

Females

-

5148 (6.79)

-

Males

-

5395 (6.99)

-

Whites

2307 (4.51)

7558 (6.71)

3254 (4.91)

Blacks

798 (8.63)

1434 (7.36)

874 (7.58)

Hispanics

361 (6.19)

887 (7.79)

376 (6.90)

Others

236 (5.36)

664 (7.02)

273 (6.22)

Large metropolitan

2218 (5.26)

5688 (6.79)

2655 (5.46)

Small metropolitan

876 (4.95)

2803 (7.05)

1283 (5.20)

Micropolitan

355 (5.44)

1161 (6.94)

505 (5.84)

Non-metro non-micropolitan

253 (5.58)

891 (7.06)

334 (5.88)

Q4-highest

831 (4.09)

2249 (6.38)

1264 (4.73)

Q3

875 (5.16)

2601 (7.19)

1267 (5.69)

Q2

919 (5.58)

2710 (6.94)

1166 (5.77)

Q1-lowest

1077 (6.28)

2983 (7.01)

1080 (5.85)

Medicare

2133 (7.56)

6901 (8.01)

2294 (6.39)

Medicaid

349 (4.86)

493 (4.49)

109 (4.99)

Private

1101 (3.42)

2753 (5.98)

2192 (4.79)

Other

119 (3.54)

396 (4.05)

182 (4.83)

Routine discharge

1764 (4.40)

5223 (6.77)

3213 (5.15)

Skilled nursing facility

966 (6.78)

3048 (7.40)

458 (6.31)

Expired

19 (1.68)

123 (2.83)

10 (1.43)

Other

953 (6.16)

2149 (7.10)

1096 (6.32)

2665 (5.43)

7398 (7.79)

4447 (5.54)

Age (years)

Gender

Race

Region

Author Manuscript

Area-level income

Insurance

Discharge disposition

Author Manuscript

Metastasis
Non-metastatic
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Metabolic syndrome present N (%)

Author Manuscript

Breast cancer

Colorectal cancer

Prostate cancer

1037 (4.75)

3145 (5.43)

330 (4.60)

No

1930 (5.06)

4444 (6.28)

4777 (5.45)

Yes

1772 (5.40)

6099 (7.82)

-

No

3490 (5.17)

8474 (6.96)

4404 (5.37)

Yes

212 (6.31)

2069 (6.65)

373 (6.71)

No. of comorbiditiesa

0.49 (0.73)

0.59 (0.81)

0.34 (0.62)

Length of stay

2.80 (3.06)

7.11 (6.47)

2.62 (2.48)

Metastatic
Cancer surgery*

Complications

a

Mean and standard deviation reported

Author Manuscript

b

Comorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia,
renal disease, liver disease, and HIV/AIDS
Row percent
Frequencies do not add up due to missing data

Author Manuscript
Author Manuscript
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Table 2

Author Manuscript

Association between metabolic syndrome (MetS) diagnosis and in-hospital mortality among patients with
cancer, Nationwide Inpatient Sample, 2007–2011
Cancer type
Breast cancer AOR (95%CI)

Colorectal cancer AOR (95%CI)

Prostate cancer AOR (95%CI)

No

Ref

Ref

Ref

Yes

0.31(0.20–0.46)

0.41(0.35–0.49)

0.28(0.16–0.49)

≧ 40 < 50

Ref

Ref

Ref

≧ 50 < 60

1.17(0.98–1.39)

1.17(1.01–1.34)

2.41(0.87–6.63)

≧ 60 < 70

1.58(1.31–1.89)

1.63(1.42–1.87)

4.56(1.68–12.36)

≧ 70

2.86(2.32–3.52)

3.40(2.96–3.90)

24.66(9.12–66.69)

Males

-

Ref

-

Females

-

0.86(0.82–0.92)

-

Whites

Ref

Ref

Ref

Blacks

1.11(0.95–1.31)

1.08(0.99–1.18)

1.04(0.85–1.28)

Hispanics

0.98(0.78–1.21)

0.91(0.82–1.03)

0.98(0.74–1.31)

Others

0.90(0.69–1.18)

1.09(0.98–1.23)

0.83(0.59–1.17)

Large metro

Ref

Ref

Ref

Small metro

1.20(1.04–1.38)

1.03(0.96–1.10)

1.02(0.85–1.22)

Micropolitan

1.48(1.21–1.82)

1.15(1.05–1.27)

1.19(0.93–1.54)

Not metro or micro

2.06(1.66–2.54)

1.25(1.12–1.39)

2.40(1.88–3.08)

Q4-highest

Ref

Ref

Ref

Q3

1.35(1.14–1.60)

0.98(0.90–1.07)

1.09(0.88–1.35)

Q2

1.15(0.96–1.38)

1.02(0.93–1.11)

1.01(0.81–1.26)

Q1-lowest

1.28(1.07–1.54)

0.98(0.90–1.07)

1.05(0.84–1.32)

Private

Ref

Ref

Ref

Medicaid

0.84(0.70–1.02)

0.91(0.80–1.03)

1.02(0.70–1.50)

Medicare

0.41(0.35–0.49)

0.66(0.61–0.72)

0.36(0.30–0.43)

Other

2.05(1.70–2.47)

1.73(1.55–1.92)

2.40(1.88–3.08)

1.43(1.31–1.57)

1.46(1.41–1.51)

1.44(1.31–1.58)

Non-metastatic

Ref

Ref

Ref

Metastatic

9.57(8.32–11.01)

2.43(2.30–2.58)

11.51(9.82–13.49)

MetS diagnosis

Age groups

Author Manuscript

Gender

Race

Region

Author Manuscript

Area-level income

Insurance

Author Manuscript

# Comorbiditiesa
Metastasis

Cancer surgery*
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Cancer type

Author Manuscript

Breast cancer AOR (95%CI)

Colorectal cancer AOR (95%CI)

Prostate cancer AOR (95%CI)

No

Ref

Ref

-

Yes

0.02(0.01–0.03)

0.43(0.40–0.45)

-

1.05(1.05–1.06)

1.04(1.03–1.04)

1.04(1.03–1.05)

Length of Stay

a

Comorbidities assessed based on ICD9 codes for the folowing: myocardial infarction, chronic heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia,
renal disease, liver disease, and HIV/AIDS

*

Cancer specific surgeries

Author Manuscript
Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Association between metabolic syndrome (MetS) diagnosis and complications among patients with cancer,
Nationwide Inpatient Sample, 2007–2011
Cancer type
Breast cancer AOR (95%CI)

Colorectal cancer AOR (95%CI)

Prostate cancer AOR (95%CI)

No

Ref

Ref

Ref

Yes

1.20(1.03–1.39)

0.93(0.88–0.99)

1.22(1.09–1.37)

≧ 40 < 50

Ref

Ref

Ref

≧ 50 < 60

1.07(0.97–1.19)

1.01(0.95–1.07)

1.10(0.94–1.28)

≧ 60 < 70

0.97(0.87–1.09)

1.03(0.97–1.09)

1.13(0.97–1.31)

≧ 70

0.92(0.80–1.06)

0.99(0.93–1.05)

0.77(0.65–0.91)

Males

-

Ref

-

Females

-

0.75(0.73–0.77)

-

Whites

Ref

Ref

Ref

Blacks

0.94(0.84–1.06)

0.86(0.82–0.90)

1.05(0.96–1.14)

Hispanics

0.93(0.81–1.07)

0.89(0.84–0.94)

1.01(0.89–1.14)

Others

0.88(0.75–1.03)

0.94(0.89–1.00)

1.06(0.94–1.21)

Large metro

Ref

Ref

Ref

Small metro

1.05(0.97–1.15)

1.04(1.00–1.07)

1.14(1.06–1.22)

Micropolitan

1.11(0.97–1.27)

1.12(1.07–1.18)

1.17(1.05–1.30)

Not metro or micro

1.09(0.93–1.28)

1.03(0.97–1.08)

1.11(0.98–1.26)

Q4-highest

Ref

Ref

Ref

Q3

1.00(0.91–1.10)

1.03(0.99–1.07)

0.98(0.90–1.06)

Q2

1.00(0.90–1.11)

0.99(0.95–1.03)

1.03(0.95–1.12)

Q1-lowest

0.92(0.82–1.03)

0.90(0.86–0.94)

0.96(0.88–1.06)

Private

Ref

Ref

Ref

Medicaid

0.89(0.78–1.01)

0.76(0.71–0.81)

0.73(0.61–0.89)

Medicare

0.98(0.88–1.09)

0.97(0.93–1.01)

0.98(0.91–1.06)

Other

0.89(0.78–1.01)

0.79(0.74–0.84)

0.91(0.79–1.05)

1.10(1.03–1.17)

0.90(0.88–0.92)

0.96(0.90–1.01)

Non-metastatic/in situ

Ref

Ref

Ref

Metastatic

0.68(0.63–0.74)

0.87(0.84–0.89)

0.30(0.24–0.56)

MetS diagnosis

Age groups

Author Manuscript

Gender

Race

Region

Author Manuscript

Area-level income

Insurance

Author Manuscript

# Comorbiditiesa
Metastasis

Cancer surgery*
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Cancer type

Author Manuscript

Breast cancer AOR (95%CI)

Colorectal cancer AOR (95%CI)

Prostate cancer AOR (95%CI)

No

Ref

Ref

-

Yes

0.83(0.77–0.90)

2.28(2.22–2.35)

-

Routine discharge

Ref

Ref

Ref

Skilled nursing facility

1.34(1.23–1.47)

1.45(1.41–1.50)

1.03(0.93–1.14)

Expired

0.57(0.40–0.80)

1.30(1.19–1.41)

0.37(0.24–0.56)

Other

1.07(0.97–1.17)

1.41(1.36–1.46)

1.09(1.01–1.18)

1.08(1.07–1.09)

1.11(1.11–1.11)

1.26(1.25–1.27)

Discharge disposition

Length of stay

a

Comorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia,
renal disease, liver disease, and HIV/AIDS

Author Manuscript

*

Cancer-specific surgeries

Author Manuscript
Author Manuscript
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Table 4

Author Manuscript

Association between metabolic syndrome (MetS) diagnosis and hospital discharge to a skilled nursing facility
as compared to regular discharge of patients with cancer, Nationwide Inpatient Sample, 2007–2011
Cancer type
Breast cancer AOR (95%CI)

Colorectal cancer AOR (95%CI)

Prostate cancer AOR (95%CI)

No

Ref

Ref

Ref

Yes

1.21(1.11–1.32)

1.06(1.01–1.11)

1.10(0.98–1.23)

≧ 40 < 50

Ref

Ref

Ref

≧ 50 < 60

1.15(1.08–1.23)

1.12(1.05–1.19)

1.03(0.86–1.22)

≧ 60 < 70

1.32(1.23–1.42)

1.20(1.13–1.27)

1.12(0.94–1.33)

≧ 70

2.38(2.20–2.58)

2.51(2.36–2.68)

2.60(2.17–3.11)

Males

-

Ref

-

Females

-

1.23(1.20–1.27)

-

Whites

Ref

Ref

Ref

Blacks

1.05(0.98–1.12)

0.81(0.77–0.84)

1.27(1.18–1.38)

Hispanics

0.98(0.90–1.07)

0.71(0.67–0.75)

0.81(0.72–0.92)

Others

0.80(0.73–0.89)

0.76(0.71–0.81)

0.79(0.68–0.91)

Large metro

Ref

Ref

Ref

Small metro

0.71(0.67–0.75)

0.87(0.84–0.90)

0.78(0.73–0.83)

Micropolitan

0.71(0.66–0.77)

0.92(0.88–0.96)

0.69(0.62–0.76)

Not metro or micro

0.57(0.52–0.62)

0.83(0.79–0.87)

0.78(0.70–0.86)

Q4-highest

Ref

Ref

Ref

Q3

0.93(0.88–0.99)

1.01(0.97–1.05)

1.09(1.01–1.18)

Q2

1.02(0.96–1.09)

0.98(0.94–1.02)

1.19(1.09–1.29)

Q1-lowest

0.95(0.89–1.02)

1.02(0.97–1.07)

1.13(1.03–1.23)

Private

Ref

Ref

Ref

Medicaid

1.01(0.93–1.10)

1.08(1.02–1.15)

1.81(1.54–2.12)

Medicare

1.67(1.57–1.78)

1.51(1.44–1.57)

1.54(1.43–1.66)

Other

0.55(0.49–0.63)

0.53(0.50–0.57)

0.71(0.60–0.83)

1.22(1.17–1.27)

1.25(1.23–1.28)

1.35(1.29–1.41)

Non-metastatic/in situ

Ref

Ref

Ref

Metastatic

1.43(1.37–1.50)

1.13(1.10–1.16)

2.02(1.86–2.19)

MetS diagnosis

Age groups

Author Manuscript

Gender

Race

Region

Author Manuscript

Area-level income

Insurance

Author Manuscript

# Comorbiditiesa
Metastasis

Cancer surgery*
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Cancer type

Author Manuscript

Breast cancer AOR (95%CI)

Colorectal cancer AOR (95%CI)

Prostate cancer AOR (95%CI)

No

Ref

Ref

-

Yes

1.52(1.46–1.59)

0.56(0.54–0.57)

-

No

Ref

Ref

Ref

Yes

1.16(1.05–1.27)

1.28(1.24–1.33)

0.96(0.87–1.07)

1.16(1.15–1.17)

1.17(1.17–1.18)

1.26(1.25–1.27)

Complications

Length of stay

a

Comorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia,
renal disease, liver disease, and HIV/AIDS

*

Cancer-specific surgeries

Author Manuscript
Author Manuscript
Author Manuscript
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